Cambium Bio has secured FDA agreement on a streamlined single pivotal Phase 3 trial for Elate Ocular®, cutting development costs and timelines. Despite a AUD 4.1 million loss for FY2026, the company strengthened its funding position and manufacturing partnerships ahead of patient dosing targeted for late 2026.
- FDA endorses single pivotal Phase 3 trial for Elate Ocular
- FY2026 net loss of AUD 4.1 million on slightly lower royalty revenue
- Raised AUD 4.57 million via equity placements at premiums during FY2026
- Manufacturing partnerships secured with Locus Cell and ZYBT
- Topline Phase 3 data expected in Q4 2027; BLA submission targeted mid-2028
FDA Greenlights Single Pivotal Trial, Cutting Costs and Accelerating Timeline
Cambium Bio Limited (ASX:CMB) has transformed its regulatory strategy for Elate Ocular®, its lead dry eye disease biologic, by securing U.S. FDA confirmation that a single adequate and well-controlled pivotal Phase 3 trial, supplemented by confirmatory evidence, will suffice for a Biologics License Application (BLA). This shift from a previously anticipated two-trial pathway slashes development costs and compresses timelines, boosting the odds of a successful regulatory submission.
The defining regulatory nod came on 22 April 2026 following a Type D meeting with the FDA’s Center for Biologics Evaluation and Research. The company swiftly amended its Investigational New Drug application in June to reflect the updated Phase 3 protocol, which the FDA has accepted without objection. The pivotal study, CAMOMILE-2, will enrol 515 patients across Australia and the U.S., using a randomized, double-masked, vehicle-controlled design with co-primary endpoints assessing both signs and symptoms of dry eye disease.
Financial Performance Reflects Investment in Phase 3 Readiness
For the full year ended 30 June 2026, Cambium Bio reported a net loss of AUD 4.1 million, a modest increase compared to the prior year’s AUD 3.8 million loss. Revenue, primarily from royalties on its human platelet lysate platform, fell slightly by 4% to AUD 642,000. However, other income surged to AUD 596,000, largely driven by R&D tax incentives.
The company maintained tight cost discipline during this pivotal development phase, with research and development expenses rising to AUD 3.26 million as it advanced manufacturing and clinical trial preparations. Corporate expenses were trimmed to AUD 1.55 million, reflecting overhead management amid the Phase 3 ramp-up.
Funding and Manufacturing Partnerships Strengthen Pipeline
Cambium Bio bolstered its cash reserves during FY2026 through equity placements totaling AUD 4.57 million, executed at premiums to market prices. Notably, a strategic placement by major shareholder ZYBT injected AUD 2.4 million at a 20% premium. Post-year end, the company raised a further AUD 1.008 million at a 17.1% premium and secured a AUD 3.75 million loan facility to pre-finance its FY2027 R&D Tax Incentive refund.
On the manufacturing front, the company formalized a memorandum of understanding with Locus Cell Co., Ltd for contract manufacturing of Elate Ocular’s Active Biologic Ingredient. Meanwhile, recurring royalty income from the FD hPL cell culture supplement products continued, with ZYBT resuming direct manufacturing and commercialisation in April 2026.
Clear Pathway to Phase 3 Execution and Commercialisation
With dual ethics approvals secured in Australia and the U.S., and a three-step orthogonal pathogen inactivation process developed to enhance viral safety, Cambium Bio is poised to manufacture its engineering and first clinical batches in the second half of calendar 2026. The company targets First Patient In for CAMOMILE-2 in Q4 2026, subject to additional funding, with topline data expected in Q4 2027 and a rolling BLA submission under Fast Track designation by mid-2028.
In parallel, Cambium Bio plans to explore structured out-licensing and regional licensing opportunities to attract non-dilutive capital and expand its commercial footprint beyond the U.S. market, where it retains global rights except for China, Singapore, and Taiwan, which are licensed to ZYBT.
Risks and Uncertainties Remain
Despite regulatory progress and funding success, Cambium Bio faces typical clinical-stage biotech risks including regulatory hurdles, funding availability, clinical trial execution, manufacturing consistency, intellectual property protection, and eventual market acceptance. The company ended FY2026 with AUD 1.1 million in cash and net current liabilities of AUD 73,000, underscoring the importance of continued capital raising and R&D tax incentive refunds to sustain operations.
The company’s directors acknowledge these risks and maintain a flexible approach to managing research and development expenditure to align with available resources. The upcoming pivotal trial commencement and subsequent data readouts will be critical milestones to watch.
Bottom Line?
Cambium Bio’s streamlined Phase 3 trial design and strengthened funding position set the stage for a critical year ahead, but successful patient enrolment and sustained capital will be essential to translate regulatory progress into commercial reality.
Questions in the middle?
- Will Cambium Bio secure sufficient funding to complete its pivotal Phase 3 trial without diluting shareholder value excessively?
- How will the single pivotal trial pathway impact the statistical robustness and regulatory scrutiny of Elate Ocular’s approval process?
- What timing and terms can investors expect from potential out-licensing or partnering deals following trial commencement?